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Erythropoietin (EPO) is used to treat anemia of cancer but is suspected to increase 
cancer mortality. EPO is also expressed in hypoxic regions of the tumor and might, 
thus, contribute to hypoxia-induced malignancies, including resistance to chemo- and 
radiotherapy. However, it is controversially discussed whether a functional EPO 
receptor (EPOR) is expressed by cancer cells. Thus, we analyzed the expression and 
function of EPOR in hypoxia-induced resistance towards chemo- and radiotherapy in 
lung cancer, the most common type of cancer accounting for the majority of cancer 
related deaths. We generated A549 and H661 EPOR knockout lung cancer cells by 
CRISPR/Cas and treated them with chemo- and radiotherapy under normoxic and 
hypoxic conditions. Our data suggests that EPOR expression is required for hypoxia-
induced resistance to chemo- and radiotherapy. However, our data show that EPO is 
not required for EPOR-dependent cancer cell protection. We can further show that 
cancer cells release a protective factor that uses EPOR to protect cancer cells in a 
paracrine way under hypoxic conditions. This factor is included in exosomes and by 
using proteomics, we identified three potential candidates that might act as alternative 
EPOR ligands. In conclusion, our data provides the novel finding, that EPOR, either 
as a homodimeric or, more likely, as a heterodimeric receptor protects cancer cells 


















Erythropoietin (EPO) wird zur Behandlung von Krebsanämie angewendet, steht 
jedoch im Verdacht, die Krebssterblichkeit zu erhöhen. EPO wird auch in 
hypoxischen Regionen des Tumors exprimiert und kann daher zu Resistenz gegen 
Chemo- und Strahlentherapie beitragen. Es wird kontrovers diskutiert, ob ein 
funktioneller EPO-Rezeptor (EPOR) von Krebszellen exprimiert wird. Daher 
analysierten wir die Expression und Funktion von EPOR bei hypoxie-induzierter 
Resistenz gegen Therapie bei Lungenkrebs, der häufigsten Krebsart. Wir haben mit 
CRISPR/ Cas A549- und H661-EPOR-Knockout-Lungenkrebszellen erzeugt und 
diese unter normoxischen und hypoxischen Bedingungen mit Chemo- und 
Strahlentherapie behandelt. Unsere Daten legen nahe, dass die EPOR-Expression für 
eine hypoxie-induzierte Resistenz gegen Chemo- und Strahlentherapie erforderlich ist. 
Sie zeigen jedoch auch, dass EPO für Schutz von Krebszellen nicht erforderlich ist. 
Wir können weiterhin zeigen, dass Krebszellen einen Schutzfaktor freisetzen, der 
EPOR verwendet, um Krebszellen unter hypoxischen Bedingungen auf parakrine 
Weise zu schützen. Dieser Faktor ist teilweise in Exosomen enthalten. Mithilfe der 
Proteomik haben wir drei potenzielle Kandidaten identifiziert, die als alternative 
EPOR-Liganden fungieren könnten. Zusammenfassend kommen wir zum neuartigen 
Befund, dass EPOR entweder als homodimerer oder wahrscheinlicher als 
heterodimerer Rezeptor Krebszellen vor Chemo- und Strahlentherapie mit einem 
















Erythropoietin (EPO) is a glycoprotein- hormone, which controls the production of 
erythrocytes from precursor cells in the bone marrow. It is a polypeptide of 165 amino 
acids and has a molecular mass of 30.4kDa [1]. In adults, 85-90% of the EPO is 
synthesized in the interstitial cells in the peritubular capillary bed of the kidneys [1]. 
EPO is a receptor ligand and essential for survival, proliferation and differentiation of 
the erythrocytic progenitors [2]. The EPO Receptor (EPOR) can exist in at least two 
different conformations: a homodimer, which consists of two identical EPOR subunits; 
or a heterodimer, comprised of an EPOR and a beta-common (βc) subunit (CD131)[3]. 
In red blood cells, EPO stimulates erythroid cell differentiation and survival via the 
EPOR homodimer [3]. So far, EPO is the only known ligand for EPOR with a high 
binding affinity to the homodimeric isoform of EPOR (~100–200 pmol/L [3]). The 
binding affinity of EPO to the EPOR heterodimer, however, is a thousand-fold lower 
[4-5], which suggest that other ligands might bind better to this form.  
EPOR is expressed in many organs such as the brain, cardiovascular system, etc., 
indicating that EPO has a biological role beyond red blood cell production. The role 
of EPO and the heterodimeric EPOR in non-hematopoietic tissues is not fully 
understood but may involve regulation of proliferation and survival in non-
hematopoietic tissue [3]. For example, EPO treatment reduces myocardial infarct size, 
protects against ischemia-reperfusion injury and promotes ventricular remodeling [2]. 
Therapeutically, recombinant human erythropoietin (rhEPO) is commonly used in 
anemic patients such as in chronic kidney disease patients to compensate the 
insufficient production of EPO in the kidney [6]. In cancer patients, EPO is used to 
treat cancer-associated or therapy-associated anemia [7], [8]. Because EPO regulates 
proliferation and survival, potentially also in cancer cells, application of EPO in 
cancer patients has been controversially discussed for years. Studies analyzing the 
impact of rhEPO treatment on in vitro cell proliferation and survival as well as the 
impact of EPO administration on mortality in cancer patients seem to be contradictory. 
While several clinical studies [9], [10], [11] do not find evidence for increased tumor 
progression during EPO administration, other studies show that EPO decreased 
survival of cancer patients [7], [12], [13]. Also, in vitro studies in hormone sensitive 





EPO treatment [12], [14] and EPO gene expression has been detected in several 
cancer cell lines.  
In vivo, EPO has been suggested to promote cancer in two ways: 1. EPO has been 
reported to increase tumor angiogenesis and might be required to maintain the 
integrity of the endothelium in tumors [2], [11], [12]. 2. EPO directly signals on 
cancer cells and selects cells with diminished apoptotic potential [12], [13], induces 
cellular proliferation [12], or protects from chemoradiation [12]. To signal on cancer 
cells, EPO requires the expression of EPOR, although a recent study suggests that 
EPO can also promote tumor growth via the ephrin-type B receptor 4 (EphB4) [15]. 
This is particularly interesting because the expression of EPOR in cancer cells has 
been doubted for many years. Although some studies reported on EPOR gene 
expression in cancer cell lines [118], no evidence for EPOR gene expression in tumor 
tissues has been reported [2]. The expression of EPOR in tumor tissues was also 
doubted because no antibodies against EPOR existed that reliably detect EPOR. 
However, recently developed antibodies against EPOR show that EPOR is expressed 
in both, human cancer cell lines and tumor tissue of human patients [16]. This finding 
fueled the ongoing debate about the role and function of EPOR in tumors. 
A strong indicator of a functional EPOR in cancer cells is the inducible gene 
expression of both EPO and EPOR in hypoxia [2] [12]. Tumor hypoxia frequently 
occurs in solid tumors when they outgrow the capillary diffusion capacity resulting in 
tumor regions that are inadequately supplied by oxygen. Tumor hypoxia is a frequent 
feature of malignancies and is often associated with treatment resistance, an 
aggressive clinical phenotype, and a poor prognosis [12]. Hypoxia in cancer leads to a 
change in the microenvironment of the tumor, which promotes apoptosis and 
autophagy, or inhibits DNA damage and mitochondrial activity through various 
signaling pathways [17]. Thereby, tumor hypoxia renders tumors insensitive to 
immunotherapy, chemotherapy or radiation [17]. Especially the efficacy of radiation 
is drastically reduced by tumor hypoxia because tumor hypoxia activates DNA 
damage signaling as well as DNA repair pathways [125]. In addition, radiation 
requires oxygen to generate reactive oxygen species that damage tumor cells [126]. 
Further, hypoxia promotes a decrease in tumor pH, which leads to multidrug 
resistance through various mechanisms [17]. These include a decreased concentration 





reduced apoptotic potential, and an increased activity of the multidrug transporter p-
Glycoprotein which is in charge of pumping out cytotoxins [17]. 
Tumor hypoxia frequently occurs in lung cancer, the leading cause of cancer related 
deaths in male patients, and the second among female patients worldwide [67- 69], 
and reduces the success of chemo- or radiation in human patients [18]. Because lung 
cancer patients often develop anemia [67], they are commonly treated with EPO. 
However, it has also been reported that co-expression of EPO/EPOR in lung cancer 
biopsies is a negative prognostic factor for early stage non-small lung cancer [12]. In 
vitro and in vivo preclinical studies show that EPOR is expressed in (A549) lung 
cancer cells [11], [16], but seems to be non-responsive to EPO [19]. Thus, it is 
possible that lung cancer cells either express non-functional EPOR or that EPOR is 
activated by different means. 
We hypothesize that EPOR, despite its non-responsiveness to EPO, has a biological 
function in lung cancer cells. To test our hypothesis, we generated A549 and H661 
EPOR knockout cells by CRISPR/Cas and analyzed their survival after radiation and 


















4. Material and Methods 
4.1  Cellculture 
 
We cultured adenocarcinomic human alveolar basal epithelial cell lines A549 and 
H661 in 10 cm petri dishes. H661 were maintained in Roswell Park Memorial 
Institute 1640 (RPMI-1640) (Gibco by life Technologies) and A549 cells were 
maintained in Dulbecco’s Minimum Essential medium (MEM) with Earle’s Salts 
(Gibco by Life Technologies). Both media were supplemented with 10% Fetal Calf 
Serum (FCS) (heat inactivated), 2ml L-glutamine, 20mM HEPES buffer solution 
(Gibco by Life Technologies), 10mM Sodium Pyruvate solution (Gibco by Life 
Technologies) and 2ml Penicillin/ Streptomycin. The cells were split when reaching 
80-100% of confluency in a 1/10 ratio. To do so, both cell lines were washed with 
Phosphate buffered saline (PBS) and incubated in 0.05% Trypsin (Gibco by life 
Technologies) for 1-2 min. The detached cells were re-suspended in 9ml of fresh 10% 
FCS medium. Cells were kept at 37° C in normoxia (21% O2 and 5% CO2) Revco 
(Thermo Scientific) or at hypoxia at 37°C (1% O2 and 5% CO2) in Hera cell 240 
incubator (Heraeus). 
Cell freezing 
To harvest cells for freezing, they were trypsinized as described above. To remove 
trypsin, cells were re-suspended in 9ml of fresh 10% FCS medium in a 50ml Falcon 
tube. The suspension was centrifuged at 180 x g for 5 min and the supernatant was 
removed. The cell pellet was resuspended in a mixture of 90% FCS and 10% DMSO. 
This mixture was then aliquoted into Cryo vials and cells were kept in a freezing 
container holding isopropanol. This container was placed in a -80°C freezer to cool 
the cells down with 1°C per minute until -80°C were reached. Lastly, the cells were 
then stored in liquid nitrogen.  
 
Cell thawing 
The cells were quickly thawed by placing them into a pre-warmed water bath at 37°C. 
The cell suspension was then added into 9ml of fresh 10% FCS medium. To remove 





at 180 x g for 5 minutes and the supernatant was aspirated. 9ml of fresh 10% FCS 
medium were added to the cell pellet and the suspension was transferred onto a fresh 
10 cm petri dish. Cells were incubated at 37°C as described above and kept in culture 
for at least a week, before using them for an experiment.  
  
 Cell counting 
10 μl of cell suspension were added to a Neubauer Chamber and covered with a cover 
glass. Cells that were within four counting grid squares were counted and this sum 
was multiplied by 2,500 to obtain the cell concentration of the suspension (cell 
number per ml).  
4.2  Identification of EPOR knockout in H661 cells 
A549 EPOR knockout cells were already generated and verified in a previous study 
[22]. The H661 knockout cell line was generated with the CRISPR/Cas9 System 
(Genescript, USA). To confirm the H661 EPOR knockout clone provided by 
Genescript we established monoclonal colonies by seeding single cells into 96 well 
plates. After growing a colony, cells were expanded in petri dishes with a 10 cm 
circumference. The genomic DNA of the different cell colonies was then isolated by 
incubating it in a homogenization buffer (50mM KCL, 10mM Tris-HCL (pH 8.3), 
0.01mg/ml Gelatine, 0.045% Nonidet P-40, 0.045% Tween 20) with 50 μg/ml 
proteinase K (New England Biolabs) over night at 55°C. Proteinase K was heat-
inactivated for 5-10 min at 95°C. The DNA extract was centrifuged for 5 min at 
14860 rpm to pellet cellular debris and the supernatant was transferred into a new 
Eppendorf tube. Genomic human EPOR DNA was then amplified with a nested 
Polymerase Chain Reaction (PCR) using the Primers as seen in Table 1. The PCR 
products were purified using the QIAquick PCR Purification KIT (50) (QIAGEN). 
The purified PCR products were cloned into pGEM-T vector (Promega) following the 
supplier’s instructions. The pGEM-T vectors were then transformed into NEB 5-α 
competent Escherichia coli (New England Biolabs) using the High Efficiency 
Transformation Protocol (New  England Biolabs) [33] to isolate individual alleles. 
Successfully transformed E.coli formed colonies on a selection plate with ampicillin. 





(QIAGEN) and sent to Microsynth for sequencing (Fig.1 A). The sequence reports 
were analyzed using BLAST NCBI [34]. The protein sequences that would result 
from these DNA sequences were determined using the ExPASy Translate Tool [35] 
(Fig.1 B). After identifying the clone with EPOR knockout on all four alleles in H661 
we used western blotting to confirm the knockout on protein levels (Fig.1 C). Western 
Blot is a common technique used to separate and identify proteins. Through the use of 
polyacrylamide gel electrophoresis (PAGE), proteins that are loaded with sodium 
dodecyl sulfate (SDS) are negatively charged and are separated by molecular weight 
through the process of migration towards the anode. Following this separation step, 
the proteins are transferred to a membrane (electroblotting) which can then be 
incubated with the antibody against the protein of interest. The primary antibody will 
directly bind the protein of interest, whereas the secondary antibody binds to the 
primary antibody. Furthermore, the secondary antibody is linked to a horseradish 
peroxidase. This will catalyze a chemiluminescence reaction, when adding detection 













Table 1 Sequences of the primers used for the nested PCR 
 
Primer nested PCR Sequence 
PCR 1 F: 5’GGG GAC AGT AAG GCG AGA AAC T 
R:5’CAA ACA GCA GGG GAC ATA CGA G  
PCR 2 F: 5’TCG GGG ATC TGC CAC TTA GA  
















































































































Fig. 1 Identifying EPOR knockout on four alleles in H661 cells.  
A: Shown is the wild type DNA sequence of the human EPOR gene, as well as the four identified alleles harboring 
a functional EPOR knockout.  Allele one contains a deletion of four base pairs (bp), the second allele a deletion of 
10 bp, the third allele a deletion of one bp, and the fourth allele shows an insertion of one bp, marked as blue. B: 
Shows the wild type human EPOR protein sequence with the erythropoietin binding domain visualized in bold 
letters. Translating the CRISPR/Cas modified DNA sequences of EPOR into protein sequences shows the loss of 
the EPO binding domain in all four alleles. The protein encoding reading frames are highlighted in red. C: The 
loss of EPOR in H661 cells was verified on protein level using Western blot analysis using the GM1201 antibody. 
b-Aktin was used as a loading control.  
 
 
To further characterize the A549 and H661 cells that were used, different proteins 
were measured via Western blotting. 
 
4.3  Clonogenic Assay 
 
 
Clonogenic Assays were performed in 25 cm2 venti cap flasks (Corning, 430168) filled 
with 5ml of medium for radiation experiments, and on six well plates for 
chemotherapy experiments filled with 3ml of medium per well. The medium for A549 
as well as H661 cells, contained 20% FCS instead of 10%. 250 A549 cells were 
seeded either into a 5 ml flask or a well of a six well plate. 750 H661 cells were 
seeded into a 5ml flask and 350 cells into a well of a six well plate. After seeding, the 
cells were incubated in normoxia for 24 hours. The cells were then either transferred 
into hypoxia, or remained in normoxia for another 24 hours. Next, the cells were then 
exposed to either chemotherapy or radiation as described below. After treatment, the 
cells were placed back into the hypoxic or normoxic chamber and incubated for six to 
eight days until colonies reached a size of approximately 50 cells. The cells were then 
stained over night with a solution containing 0.5% Crystal-Violet and 0.6% 
Glutaraldehyde. The solution was then removed, and the flasks or wells were washed 
with distilled water. After drying, all colonies with more than 50 cells were manually 
counted using a microscope by a blinded researcher. The number of treated cells was 
 








normalized to the number of untreated control cells and results are shown in 




The corning flask caps were tightly closed inside the hypoxic or normoxic 
incubators to prevent any gas exchange. The cells were transported to the 
radiation unit and exposed to a single dosage radiation (0,1,2 or 3 Gray (Gy)) 
with a 6 megavolt (MV) linear accelerator (Clinac iX, Varian, Palo Alto, CA, 
USA) using photons. Afterwards, they were placed back into the normoxic or 
hypoxic incubator, where the caps were re-opened inside the incubator for 
normal gas exchange.  
 
Chemotherapy 
Cells were treated either with Gemcitabine (TEVA Pharma) or Taxol 
(1152601, Bristol-Myers Squibb). Concentrations of 0,1,2,3,4 and 5 ng/ml of 
chemotherapeutics were used. 
 
Wildtype and EPOR knockout preconditioned medium 
A549 and H661 Wild type (WT) and EPOR knockout (EPORKO) cells were 
split in a ratio of 1 to 10, seeded onto 10 cm plates and incubated for 72 hours 
with 20 % FCS medium. Plates were then incubated either in hypoxia or 
normoxia for 24 hours. The preconditioned medium was then collected in 
50ml Falcon tubes and centrifugated at 180 g for 5 min to remove cell debris. 
The supernatant, i.e. the debris free preconditioned medium, was collected. 
Pre-seeded (24 h) A549 or H661 cells were incubated with the preconditioned 
medium for 24 hours. Afterwards, they were then treated or not with either 3 
Gy radiation or 1.5 ng/ml (A549 cells) as well as 2 ng/ml (H661) Gemcitabine 
and incubated until colonies grew.   
 
 Boiling the preconditioned medium 
As a negative control, parts the aforementioned preconditioned 





down, the medium was applied to A549 cells as described above. The 
cells were treated with 1.5ng/ml Gemcitabine 24 hours later and 
incubated until colonies grew.   
 
Exosome Extraction  
Preconditioned medium of normoxia or hypoxia exposed A549 cells, 
which contained 20% of exosome depleted FCS (Thermofisher, Cat 
A2720803), were centrifuged to remove the remaining cell debris. 
Exosomes were extracted using the Exosome Purification Kit (EX01- 
Exo Spin- Cell Guidance Systems) and diluted in fresh 20% FCS 
medium. Pre-seeded (24 h) A549 cells were incubated with exosome 
containing medium. They were then treated with 0ng/ml or 1.5ng/ml 
Gemcitabine 24 h later, and incubated until colonies grew.  
 
Recombinant Human Erythropoietin Treatment 
A549 cells were seeded and 24 or 48 hours afterwards, cells were treated with 
5 units/ml of rhEPO (Recormon; Roche). 24, 2, and 0.5 hours after EPO 
treatment, cells were irradiated with 0 or 3 Gray and incubated until colonies 
grew.  
 
Soluble EPOR and EPOR Blocking Peptide EMP9 treatment 
A549 wild type cells were seeded and incubated for 24 h in normoxia. Right 
before the cells were placed in either normoxia or hypoxia, 0.5μg/ml of 
soluble EPOR [77] (NS0-307-ER, R&D Systems) or 5μg/ml of EMP9 [78] 
with the sequence (N to C) GGTYSCHFAPLTWVCKPQGG (SP190977, 
Biomatik) was applied and cells were incubated for 24 hours. Afterwards they 
were irradiated with 3 Gy or not (controls) and incubated at normoxia or 
hypoxia until colonies grew.  
 
Growth Factor treatment 
0.05μg/ml Stem Cell Factor (NBP2-35256, Novus Bio), 12.5μg/ml 
Thrombospondin-1(NS0- 3074-TH, R&D Systems), or 1.0μg/ml Ephrin B2 





24 h after seeding. 24 h after incubation with growth factors, the cells were 
treated with 0ng/ml or 1.5ng/ml Gemcitabine or not (controls) and incubated 
in normoxia until colonies grew.  
4.4  Erythropoietin activity in Mice 
 
 
In this study we verified the activity of EPO used for our in vitro assays. We used 
eight female mice with a mixed background comprised of FVB, C57Bl/6 and 129S, 
that were 36 weeks of age. The mice were housed at 22±5 °C in a 12h light/dark cycle 
and fed rodent chow and water freely. The mice were intraperitoneally injected with 
either 100 µl 300units/kg of rhEPO (Recormon; Roche) or 100 µl saline three times a 
week (Monday, Wednesday, and Friday) for two weeks. Three days after the last 
injection, the mice were euthanized by carbon dioxide (CO
2
). After opening the chest 
cavity to expose the heart, 0.5-1ml of blood were collected by punctuating the right 
ventricle with a 1ml G21 syringe that contained heparin on the inside. The hematocrit 
was determined by filling capillaries with blood, centrifuging the capillaries for 5 min 
at 120rpm in the microcentrifuge (HETTICH), and calculating the ratio of volume of 
the red blood cell pellet to the entire blood volume (%). The hemoglobin was 
measured using the ABL800 (Radiometer RSCH GmbH).  
4.5  RNA Extraction, cDNA Synthesis and Real-time PCR  
 
 
To extract the RNA from in vitro cultivated cells, the ReliaPrep RNA Cell Miniprep 
System was used. Briefly described, 1- Thioglycerol was freshly added to the LBA 
buffer that was supplied with the kit before the RNA extraction. The cells on 6 well 
plates were washed with cold PBS. After aspirating the PBS, cells were incubated 
with 250μl of the 1-Thioglycerol LBS mix. The cells were scraped off the plates and 
the cell suspension was transferred into an Eppendorf tube, which was kept on ice. To 
complete the cell lysis, the cells were passed through a 21G syringe several times and 
the lysate was centrifugated at 16 g for 5 min. The supernatant was transferred to a 
ReliaPrep Minicolumn in a collection tube, kept at room temperature, and centrifuged 
with the same conditions as above. After the flow through was discarded, an RNA 





Again, the flow through was discarded and the columns were incubated with DNaseI 
mix, which was prepared following the instructions in the protocol, for 15 min at 
room temperature. Afterwards, a column wash solution was directly applied without 
prior centrifugation. The wash solution was removed by centrifugation and the 
process was repeated once. To eluate RNA from the columns, 30μl of RNA free water 
was added to the columns and the columns were centrifugated. The RNA quantity 
was assessed by measuring its absorption at 260 nm using the NanoDrop 2000 
Spectrophotometer and RNA quality was determining the ratio of 260/280 as well as 
260/230. The RNA was either stored at -80°C or directly transcribed into cDNA.	
To transcribe the RNA into cDNA, 10μl of RNA (100ng/μl) was incubated with 1μl 
of Oligo dT (10μM; Promega) for 5 minutes at 65°C. The mix was placed on ice for 
another 5 minutes. The samples were then incubated with 15μl of master mix (5.57 μl 
H2O, 5 μl 5x Reaction Buffer for RT (Thermo Fischer), 2.5 dNTPs (15 mM each, 
Thermo scientific), 1 μl RNasin (Promega), 0.25 μl 100x BSA (New England Biolaps) 
and 0.5 μl Revert Aid Reverse Transcriptase (Thermo scientific) for 2 hours at 42°C. 
The reaction was inactivated by incubating the samples at 65°C for 10 minutes. To 
obtain a cDNA concentration of 5ng/μl, 175 μl of H2O were added. Samples were 
stored at -20 °C or directly used for real time PCR. 
For real time PCR a master mix with 5μl PowerUp SYBR Green master mix 
(ThermoFisher, Cat A25743), 1μl Primer forward (10 μM), 1μl Primer reverse (10 
μM) and 1μl of SYBR H2O was prepared on ice and 7.5 µl of the mix were pipetted 
into a well MicroAmp Fast Optical 96-Well Reaction Plate (Applied Biosystems by 
life technologies). After adding 2 μl of cDNA (5ng/μl), the plate was sealed with 
Optical Adhesive Covers (Applied Biosystems by Life Technologies), and 
centrifuged for a few seconds at 2500 x g, before being placed in Thermocycler 
ABI7500 Fast (Applied Biosystems). The Amplification profile was as follows: 50° C 
for 2 min; 95° C for 10 min; 40 cycles at 95° C for 30 sec and 60° C for 40 sec, 
followed by melt curve analysis. The samples were run in duplicates and the results 
obtained were normalized to β-actin (reference gene) and fold changes were 
calculated using the ΔΔCt method [79] with the following formulae:  





      ΔΔCt= (CtTarget – CtReference) sample – (CtTarget – CtReference) calibrator   
      Fold change= 2ΔΔCt  
The primers used for real time PCR were designed using the Primer3 Software [39] 
[40] and ordered from Microsynth. Primer quality was assessed by the melting Curve 
analysis after the real time PCR run, as well as by gel electrophoresis to determine the 
size and purity of the product. The primer sequences are shown in Table 2.  
 
Table 2 Primer sequences used for RT- PCR. 
 
Target Gene Primer Sequence 
Human b-Aktin Fwd: 5’ CTGGAACGGTGAAGGTGACA 3’ 
Rev: 5’ AAGGGACTTCCTGTAACAACG 3’ 
ATG 5  Fwd: 5’ ATGTGCTTCGAGATGTGTGG 3’ 
Rev: 5’ CATTTCAGTGGTGTGCCTTC 3’  
ATG 6 Fwd: 5’ AGGTTGAGAAAGGCGAGACA 3’ 
Rev: 5’ AGGACACCCAAGCAAGACC 3’ 
ATG 7 Fwd: 5’ TGGAACAAGCAGCAAATGAG 3’ 
Rev: 5’ AGACAGAGGGCAGGATAGCA 3’  
ATG 12 Fwd: 5’ AGTAGAGCGAACACGAACCA 3’ 
Rev: 5’ GGGAAGGAGCAAAGGACTGA 3’  
CD131 Fwd: 5’ AATGTGTGGATGTGAGACTGAGG 3’ 
Rev: 5’ GCCATAGAGAAAGCAAGGTAACAAA 
3’ 
H661 EPOR Fwd: 5’ GGGGACAGTAAGGCGAGAAAC 3’ 
Rev: 5’ CAAACAGCAGGGGACATA CGA 3’ 
YWHAZ (14-3-3 Zeta Protein)  Fwd: 5’ CCGTTACTTGGCTGAGGTTG 3’ 
Rev: 5’AGTCTGATAGGATGTGTTGGTTG3’ 
CLU (Clusterin)  Fwd: 5’ GAGACCAGGGAATCAGAGACA 3’ 
Rev: 5’ TTTCAGGCAGGGCTTACACTC 
ICOSLG (B7RP1) (inducible T cell 
costimulator ligand)  
Fwd: 5’ CCACTCCAGACCTCCCTTCCTC 3’ 






4.6  Western Blot 
 
 
To analyze the proteins of in vitro cultivated cell lines, the cells were lysed with RIPA 
Buffer (20 mM Tris, 150 mM Sodium chloride, 1% Triton X-100, 1% Na-
deoxycholate, 0.1% SDS) directly on the plate and the lysate was kept in Eppendorf 
tubes on ice. To determine the protein concentration, we used the Pierce 
Bicinchoninic Acid (BCA) Protein. Protein lysates were incubated with a sample 
buffer containing 5% SDS and 5 % beta-mercapto-ethanol, an SDS- PAGE gel was 
casted (Table 3), and the protein lysates were loaded on the SDS-PAGE gel.  
 
Table 3 Ingredients for the SDS-PAGE Mix Western Blot Gel  
 
Layer Separation Collecting Gel 
Dest H2O (ml) 6.8 3.6 
1.5M Tris, pH 8.8 
(ml) 
3.0 - 







10% SDS (μl) 150 50 
10% APS (μl) 50 35 
TEMED (μl) 7.5 10 
 
The gel was run at constant 15mA for 15 min, and then at constant 25mA for 60 
minutes (Bio- Rad Power Pac 1000). The separated proteins were transferred to a 
nitrocellulose blotting membrane (GE Healthcare Life Science) at 1000 mA for about 
2 hours. After the transfer, the membrane was blocked using 5% milk (Rapilait, 
Migros, Schweiz) in Tris buffered saline (pH 7.5) containing 0.3% Triton X-100 





1:200 (GM1201; Adlevon), mouse anti EPOR BCO-4B5-C9 1:500 (not available 
anymore; Adlevon), rabbit Vimentin (R28) (3932S; Cell Signaling) 1:500, mouse E-
cadherine (ab1416; Cell Signaling) 1:500, Snail (C15D3) Rabbit mAb (3879S; Cell 
Signaling) 1:500,  rabbit anti Cyclin D1(2922; Cell Signaling) 1:200, and mouse mAb 
Cyclin E (4129; Cell Signaling) 1:200. The membranes were incubated in antibody 
solutions over night at 4°C. After washing them three times with TBST, the 
membranes were incubated with HRP conjugated secondary antibodies, which were 
diluted in 5% milk in TBST: 1:5000; goat anti-rat (sc-2032; Santa Cruz), donkey-anti-
rabbit (NA934V; Amersham), and goat-anti-mouse (Santa Cruz sc-2031). To 
visualize the protein bands, the membranes were incubated with Super Signal West 
Femto Maximum Sensitivity Substrate (Thermo Scientific) for a few minutes and 





















5.1  Hypoxia-inducible resistance to chemo- and radiotherapy is EPOR- 
dependent.  
 
To analyze the role of EPOR on hypoxia-induced resistance to chemo- and 
radiotherapy, we used the previously described A549 WT and EPORKO as well as 
our newly established H661 WT and EPORKO lung cancer cell lines. Both cell lines 
responded adequately to hypoxia as exemplified by the hypoxia-induced expression 
of Egln1 (supplemental, Fig.1). Additionally, A549 WT and EPOR as well as H661 
WT and EPOR formed colonies in a clonogenic assay. We used this assay to 
determine the survival of normoxia and hypoxia exposed A549 WT (Fig.2 A) and 
EPORKO (Fig.2 B) cells at different concentrations of Taxol. Survival of both, A549 
WT and EPOKO cells, decreased in a dose-dependent manner under normoxia as well 
as hypoxia. However, hypoxia exposed A549 WT but not EPORKO cells had a better 
survival rate than normoxia exposed cells. When A549 WT cells were incubated with 
1.5 ng/ml Taxol the survival rate increased from 28% at normoxia to 47% at hypoxia 
(p<0.05). However, the survival rate of A549 EPORKO cells decreased from 30% at 
normoxia to 18% at hypoxia (Fig.2 A and B). This indicates that EPOR WT but not 
EPOR deficient A549 cells were protected from Taxol by hypoxia exposure. In 
addition, we analyzed the response of H661 lung cancer cells to Taxol to confirm that 
the effect is not only cell line-specific. H661 cells showed a similar pattern: Taxol-
exposed EPOR wild type cells displayed better survival rates under hypoxia than 
under normoxia (Fig.2 C). This effect was lost in EPORKO cells, which were not 
protected from Taxol under hypoxia (Fig.2 D). 
In a further experiment, we exposed normoxic and hypoxic H661 lung cancer cells 
with and without EPOR expression to different concentrations of Gemcitabine, which 
is a common therapeutic used for advanced lung cancer patients [80]. When H661 
WT cells were incubated with 3ng/ml Gemcitabine, the survival rate increased from 
21% at normoxia to 33% at hypoxia (p<0.05). However, the survival rate of H661 
EPORKO cells did not differ between normoxia and hypoxia (Fig.2 E and F). This 
shows that EPOR WT but not EPOR deficient H661 cells were protected from 





cancer cells to radiation. Radiation-exposed EPOR wild type cells displayed better 
survival rates under hypoxia than under normoxia (Fig.2 G). At a radiation dose of 3 
Gy, the H661 WT cells showed a survival rate of 58% under hypoxia, whereas under 
normoxia the survival rate was only 40% (p<0.05). This effect was lost in EPORKO 
cells, which were not protected from Radiation under hypoxia (Fig.2 H). 
Our data suggest that hypoxia exposure induces a general resistance to chemo- and 
radiotherapy in lung cancer cells and that the resistance depends on the expression of 














Fig. 2 EPOR dependent hypoxia-inducible resistance to chemotherapy and radiotherapy in A549 and H661 lung 
cancer cells 
A549 and H661 lung cancer wildtype cells (WT) and EPO receptor knockout cells (EPORKO) were incubated 
either in normoxia (21% O2, black bar; Nx) or hypoxia (1% O2, gray bar; Hx) and treated with different 
concentrations of Taxol, Gemcitabine or Radiation. The survival rate was analyzed by clonogenic assay and is 
shown relative to untreated controls of the respective EPOR expressing or deficient cell line in percent (%). 
Panel A shows A549 WT and panel B shows A549 EPORKO lung cancer cells exposed to an increasing 
concentration of Taxol (X-axis) under normoxic (black) and hypoxic (gray) conditions (n=3). C and D show H661 
WT (C) and EPORKO (D) lung cancer cells exposed to an increasing concentration of Taxol under normoxic 
(black) and hypoxic (gray) conditions (n=3). Panel E shows H661 WT, and Panel F shows H661 EPORKO cells 
that are exposed to an increasing concentration of Gemcitabine under normoxic (black) and hypoxic (gray) 
conditions (n= 3). G illustrates H661 WT and H illustrates H661 EPORKO cells that are exposed to an increasing 
dose of radiation under normoxic (black) and hypoxic (gray) conditions (n=3).  Shown is the percentage of 
survival (Y-axis) normalized to untreated WT and EPOR knockout cells in %.  A Students t-test was performed for 
statistics. (Mean ± SD; n=3-4; *= 0.01≤p<0.05, **= 0.001≤p<0.01, *** = p <0.001 
 
5.2  Autophagy is not involved in EPOR-mediated protection from 
chemo- and radiotherapy 
 
Radiotherapy increases DNA damage and induces DNA repair mechanisms [84]. 
Thus, it is reasonable to assume that hypoxia-driven cell protection from radiation 
involves DNA repair mechanisms to prevent cell death [85]. However, a previous 
study in our lab showed that neither DNA damage nor repair mechanisms are 
involved in the hypoxia-induced protection of A549 lung cancer cells from radiation 
[22]. Radiation-induced autophagy often protects cells from cytotoxic stimuli [86], 
[127]. Initially it can prevent or at least delay the formation of tumor by protecting the 
cell from potentially damaging species that might lead to mutational and carcinogenic 
damage. However, once tumor formation has progressed, autophagy can protect the 
tumor cell from environmental injury. In radio- and chemotherapy, the induction of 
autophagy is frequently thought to perform an additional cytoprotective function by 
preventing cell death through apoptosis [86]. Because EPO can suppress apoptotic 
cell injury through autophagy [87], we compared the mRNA expression of the 
relevant autophagy genes ATG 5, 6, 7, and 12 of normoxia and hypoxia exposed 
A549 WT and EPORKO cells (Fig.3). The expression of ATG 5, a key protein, is 
reduced 1.2 times (p>0.05) in both, hypoxia exposed A549 WT as well as EPORKO 
cells (Fig.3, A; B, respecitively). Furthermore, the expression of ATG 6 did not differ 
between normoxia and hypoxia exposed A549 WT cells (Fig.3 C). Additionally, ATG 
6 expression increased three times (p>0.05) in A549 EPORKO cells under hypoxic 
conditions (Fig.3 D). ATG7 expression was increased in hypoxic conditions in both, 
A549 WT (Fig.3 E) and A549 EPORKO (Fig.3 F) cells. In the A549 WT cells, the 





The expression of ATG12 increased 1.22-fold (p>0.05) in the A549 WT cells under 
hypoxic conditions (Fig.3 G), whereas ATG12 gene expression could not be 
measured in hypoxia exposed A549 EPORKO cells (Fig.3 H). In summary, the data 
on autophagy gene expression were mixed and show no clear indication of an EPOR 
dependent activation of autophagy in lung cancer cells under hypoxia. Thus, we 
conclude that the EPO-EPOR driven induction of autophagy is not involved in the 













Fig.3 Autophagy- related Genes (ATG) Real Time PCR Results 
Real Time PCR was performed using cDNA of the A549 lung cancer wildtype cells (WT) and EPO receptor 
knockout cells (EPORKO) that were cultured in normoxic (21% O2; black bars) and hypoxic (1% O2; gray bars) 
conditions. The results obtained were normalized to β-actin (calibrator) and fold changes were calculated using the 
ΔΔCt method. The samples were run in duplicates. Panels A and B show ATG5 expression of A549 WT cells (A) 
(n=3), and A549 EPORKO cells (B) (n=3). Panels C and D show ATG6 expression of A549 WT cells (C) (n=3), 
and A549 EPORKO cells (D) (n=3). Panels E and F show ATG7 expression of A549 WT cells (E) (n=3), and 
A549 EPORKO cells (F) (n=3). Panels G and H show ATG12 expression of A549 WT cells (G) (n=3), and A549 
EPORKO cells (H) (n=3). A Students t-test was performed for statistics. (Mean ± SD; n=3-4;  
*= 0.01≤p<0.05, **= 0.001≤p<0.01, *** = p <0.001 
 
5.3  Erythropoietin is not required for EPOR-mediated protection from 
chemo- and radiotherapy  
 
 
As shown before by N. Jänicke [22] and in Figure 2, EPOR contributes to hypoxia 
induced therapy resistance. Thus, it seems plausible that the ligand of EPOR, 
erythropoietin (EPO), induces protection from chemo- and radiotherapy in lung 
cancer cells, which has been discussed since the early 2000s [2], [7], [12], [13]. On 
the other hand, A549 cells were reported not to respond to EPO [124]. To test the role 





WT cells with 1 and 2.5 u/ml EPO under normoxic conditions prior to radiation with 
3 Gy (supplemental Fig.3). However, EPO treatment did not protect A549 WT cells 
from radiation. We further incubated WT and EPORKO A549 and H661 lung cancer 
cells with a higher dose of 5 u/ml EPO under normoxic conditions, 0.5 and 2 hours 
prior to radiation with 3 Gy. Our data show that EPO treatment did neither protect 
A549 WT nor EPORKO cells from radiation, when EPO was applied 0.5 (Fig.4 A) or 
2 hours (Fig.4 B) prior to radiation. Similarly, H661 WT and EPORKO cells were not 
protected by EPO when treated 0.5 (Fig.4 C) or 2 hours to prior radiation (Fig.4 D). 
Next, we tested if lung cancer cells might require both, hypoxia exposure and EPO 
stimulation, to survive anti-cancer treatment. Therefore, we incubated A549 WT cells 
either in normoxia or hypoxia with and without 5 u/ml EPO and treated them with 
1.5ng/ml Gemcitabine. As seen before, A549 WT cells showed increased survival at 
hypoxia. However, EPO administration did not further improve survival of A549 WT 
cells in neither normoxia nor in hypoxia (Fig.4 E). 
To verify that EPO used for in vitro experiments was active, we injected mice and 
analyzed their hematocrit and hemoglobin. Injection with 300 u/kg EPO increased 
hematocrit from 48% to 77% (p<0.001), as well as hemoglobin from 132 to 227g/l 
(p<0.001) (Fig.4. F). Thus, we concluded that the EPO was active and that the 
hypoxia-induced protection of lung cancer cells from chemotherapy and radiation was 
independent of administered EPO. 
A549 lung cancer cells hardly express endogenous Epo mRNA levels under normoxia 
and hypoxia [22]. However, because cells in vitro are cultivated in 10-20% heat-
inactivated FCS, it might be possible that bovine EPO in FCS is sufficient to bind and 
fully activate the human EPOR in in vitro cultivated lung cancer cells. Thus, we 
incubated A549 (Fig.4 G) as well as H661 (Fig.4 H) WT cells with 0.5ug/ml of 
soluble EPOR (sEPOR) 24 hours prior to radiation. Although it is not clear if bovine 
EPO can activate human EPOR [57], we assume that, if bovine EPO binds to human 
EPOR on cancer cells, it can also be sequestered by sEPOR. As shown above, 
exposure to hypoxia increased the survival of irradiated A549 and H661 WT cells 
from approximately 60% to 80% (p>0.05). However, the incubation with sEPOR did 
not prevent the hypoxia-driven protection from radiation, which suggests that EPO 
(either endogenously produced by the hypoxia-exposed cancer cells or residual bovine 





supported by using the EPOR antagonizing peptide EMP9 [81]. A549 WT cells were 
either kept at normoxia or hypoxia and radiated with 3 Gy. The survival rate of 
hypoxia exposed cells increased from 61% to 79% (p>0.05) but EMP9 did not prevent 










           
 
Fig. 4 Hypoxia-induced therapy resistance against Gemcitabine and radiation is EPO independent. 
A549 and H661 lung cancer wildtype cells (WT) and EPO receptor knockout cells (EPORKO) were incubated 
either in normoxia (21% O2, Nx) or hypoxia (1% O2, Hx) and treated with 1.5ng/ml Gemcitabine or 3 Gy radiation. 
The survival rate was analyzed by clonogenic assay and is shown in percent (%) to untreated controls of the 
respective EPOR expressing or deficient cell lines. Panels A and B show survival of in normoxia (21 %) cultivated 
A549 WT and EPORKO in response to 3 Gy radiation. Either 0.5h (A) (n=3) or 2h (B) (n=3) prior to radiation, 
cells were incubated with 5 u/ml EPO (gray bars) or not (black bars). Panels C and D show survival of in normoxia 
(21 %) cultivated H661 WT and EPORKO in response to 3 Gy radiation. Either 0.5h (C) (n=3) or 2h (D) (n=3) 
prior to radiation, cells were incubated with 5 u/ml EPO (gray bars) or not (black bars). Panel E shows survival of 
in normoxia (21%) or hypoxia (1%) cultivated A549 WT cells in response to 1.5ng/ml Gemcitabine after the cells 
were incubated with 5 u/ml EPO (gray bars) or not (black bars) (n=3). Panel F displays the efficacy of the EPO 
used. It shows the increase in hematocrit (%) and hemoglobin (g/L) of mice treated with EPO (gray bar), or with 
NaCl (black bar) (n=4). Panels G and H show survival of in normoxia (21 %) or hypoxia (1%) cultivated A549 
WT (G) (n=3) and H661 WT (H) (n=1) in response to 3 Gy radiation. Cells were incubated with 0.5ug/ml of 
sEPOR (gray bars) or not (black bars). Panel I shows survival of the A549 WT cells cultivated in normoxia (21%) 
or hypoxia (1%) in response to 3 Gy radiation (n=3). Either 5ug/ml EMP9 were applied (gray) or not (black). A 







5.4  Hypoxia-induced protection is mediated by a secreted factor 
 
Hypoxia protects A549 and H661 lung cancer cells from radiation as well as Taxol 
and Gemcitabine. We showed that this protection requires the expression of EPOR. 
However, it does not require EPO. Because cytokine receptor activation, i.e. EGFR, 
has been suggested to be non-ligand induced [82], it is possible that EPOR is 
activated by hypoxia, however non-ligand induced. To test if cell secreted factors (i.e. 
paracrine activation) are required to mediate protection from radiation and 
chemotherapy, we collected the medium of A549 and H661 cells either exposed to 
normoxia or hypoxia (preconditioned medium). We observed that hypoxia 
preconditioned medium protects A549 and H661 lung cancer cells from Gemcitabine 
and radiation in a clonogenic assay: The survival rate of Gemcitabine-treated A549 
WT cells increased from 51% in normoxia preconditioned medium to 69% in hypoxia 
preconditioned medium (p<0.01) (Fig.5 A). In contrast A549 EPORKO cells showed 
no increased survival rate, when incubated in a hypoxic preconditioned medium 
(Fig.5 A). Similarly, the survival rate of Gemcitabine-treated H661 WT cells but not 
of H661 EPORKO cells increased from 52% in normoxic preconditioned medium to 
64% in hypoxic preconditioned medium (p<0.01) (Fig.5 B). Furthermore, the survival 
rate of 3 Gy radiated A549 (Fig.5 C) and H661 (Fig.5 D) WT but not EPORKO cells 
increased from 52% and 53%, respectively in normoxic preconditioned medium, and 
to 62% and 64%, respectively, in hypoxic preconditioned medium (p<0.05). These 
data suggest that a factor, which protects cancer cells via EPOR, is produced and is 
secreted by hypoxia exposed cancer cells. To test if the secreted factor is a protein, we 
boiled the normoxic and hypoxic preconditioned medium to denaturate proteins. 
While hypoxic preconditioned medium increased the survival rate of Gemcitabine 
treated A549 WT cells from 76% in normoxic preconditioned medium to 83% 
(p<0.01), no difference between Gemcitabine-treated cells incubated in boiled 
normoxia or hypoxia preconditioned medium was observed (Fig.5 E). Thus, we 
conclude that activation of EPOR for protecting lung cancer cells from chemo- and 
radiotherapy is not auto-activated by hypoxia. Instead, EPOR seems to require a 









Fig. 5 Hypoxia-induced therapy resistance depends on EPOR  
The survival rate of A549 and H661 lung cancer wildtype cells (WT) and EPO receptor knockout cells (EPORKO) 
was analyzed by clonogenic assay, after the cells were treated with Gemcitabine (A549 = 1.5ng/ml, H661= 
2ng/ml), or radiation (3Gy). Beforehand they were kept in either normoxic (21% O2 ) or hypoxic (1% O2 )  
preconditioned medium. The survival rate was analyzed by clonogenic assay and is shown in percent (%) to 
untreated controls of the respective EPOR expressing or deficient cell lines. Panels A and B show survival of in 
normoxic (21%, black), or hypoxic (1%, gray) preconditioned medium cultivated A549(A) (n=3) and H661 (B) 
(n=3) WT and EPORKO cells, in response to Gemcitabine treatment. Panels C and D show survival of in 
normoxic (21%, black), or hypoxic (1%, gray) preconditioned medium cultivated A549(C) (n=3) and H661 (D) 
(n=3) WT and EPORKO cells, in response to radiation treatment. Panel E shows in normoxic (21%, black) or 









The preconditioned medium was either boiled before application (BPcM), or not (PcM).  A Students t-test was 
performed for statistics. (Mean ± SD; n=3-4; *= 0.01≤p<0.05, **= 0.001≤p<0.01, *** = p <0.001 
 
5.5  Hypoxia-induced therapy resistance is mediated by Exosomes 
 
To characterize the EPOR ligand that protects lung cancer cells from chemo- and 
radiotherapy, we harvested preconditioned medium and isolated protein fractions of 
different size. In a previous thesis, it was shown that the fraction with proteins larger 
than 100 kDa confers EPOR dependent protection of A549 lung cancer cells from 
radiation (Fig.6 A) [22]. Because most of the receptor ligands are smaller than 100 
kDa [22], we hypothesized that exosomes, produced from hypoxia exposed cells, 
protect lung cancer cells from chemo- and radiotherapy. Exosomes are small vesicles 
that contain DNA, RNA, as well as proteins including receptor ligands [83]. The 
involvement of a receptor ligand transported by exosomes was supported by an 
experiment, where proteins larger than 100 kDa were removed from the hypoxia 
preconditioned medium. The medium, deprived of all molecules larger than 100 kDa, 
was still able to protect A549 lung cancer cells from radiation (Fig.6 B). This suggests 
that a normal receptor ligand is produced during hypoxia, which is both directly 
released into the medium as well as packed into exosomes. To test that assumption, 
we isolated exosomes from normoxia as well as hypoxia preconditioned medium and 
incubated A549 WT and EPORKO cells in it, prior to the Gemcitabine treatment. Our 
data show that exosomes isolated from hypoxia preconditioned medium increase the 
survival rate of Gemcitabine exposed A549 WT but not EPORKO cells from 72% to 
87% (p<0.05) (Fig.7) 
Our data suggests that the factor that protects lung cancer cells from chemo- and 
radiotherapy via EPOR is secreted under hypoxic conditions and is, at least partially, 


















Fig. 6 Radiation therapy resistance in A540 WT cells in medium <100 kDa   
Panel A was taken with permission from the Dissertation of Nadine Jänicke [22]. Colony formation was analyzed 
via clonogenic assay after radiating the A549 WT and EPORKO cells with 3 Gy. Data was normalized to non-
irradiated control in % (Y-axis). The preconditioned medium was preconditioned on WT cells for 24h in either 
normoxic (21% O2; white bars) or hypoxic (1%O2; black bars) conditions. This preconditioned medium (PC) was 
filtered by 100 kDa centrifugal filtration to remove all substances smaller than 100 kDa. WT and EPORKO cells 
were treated with the filtered, preconditioned medium 24h before the radiation treatment (3 Gy). Panel B shows 
the survival rate of A549 wildtype cells (WT) cultivated in normoxic (21%, black), or hypoxic (1%, gray) 
conditions, after radiotherapy with 3 Gy (n=2). The survival rate was analyzed by clonogenic assay and is shown 
in percent (%) to untreated controls of the respective EPOR expressing or deficient cell lines. A Students t-test was 
performed for statistics. (Mean ± SD; n=3-4; *= 0.01≤p<0.05, **= 0.001≤p<0.01, *** = p <0.001 
 
 






Fig. 7 Hypoxia-induced therapy resistance is mediated by Exosomes  
The survival rate of A549 lung cancer wildtype cells (WT) and EPO receptor knockout cells (EPORKO) was 
                                               






analyzed by clonogenic assay, after the application of extracted Exosomes, and radiotherapy (3 Gy) (n=3). 
Beforehand they were kept in either normoxic (21% O2 , black) or hypoxic (1% O2 , gray) preconditioned medium. 
The survival rate was analyzed by clonogenic assay and is shown in percent (%) to untreated controls of the 
respective EPOR expressing or deficient cell lines. A Students t-test was performed for statistics. (Mean ± SD; 
n=3-4; *= 0.01≤p<0.05, **= 0.001≤p<0.01, *** = p <0.001  
5.6  Alternative EPOR ligand candidates 
 
To identify the factor that protects lung cancer cells via EPOR from chemo- and 
radiotherapy, we identified three potential candidates by literature research, which 
have been reported to be associated with EPO/EPOR activity: Stem cell factor (SCF) 
and Ephrin B2 (EFNB2) have been reported to be packed into extracellular vesicles 
[63]. SCF is a growth factor, which is required during EPO-induced maturation of 
erythroid progenitor cells during erythropoiesis [88] and either exists as a secreted or 
a membrane bound isoform, the latter potentially in the membrane of secreted vesicles 
[64]. The receptor of EFNB2 has previously been reported as being able to bind EPO 
[15] and thus, it might be possible that EFNB2 also binds EPOR. Furthermore, EPO 
seems to induce Thrombospondin-1 (THBS1) [89], the third potential candidate, 
whereas Thrombospondin-1 seems to be associated with liver metastasis and poor 
prognosis [65]. Thus, we tested if the in silico identified candidates SCF, EFNB2 and 
THBS1 protect A549 WT but not EPORKO cells from Gemcitabine. However, all 




















Fig 8: Application of the Growth Factors 
The survival rate of A549 lung cancer wildtype cells (WT) and EPO receptor knockout cells (EPORKO) was 
analyzed by clonogenic assay, after the application of Ephrin B2, Stem Cell Factor, and Thrombospondin-1. Panel 
A shows survival of in normoxia (21 %) cultivated A549 WT and EPORKO in response to Gemcitabine treatment. 
Prior to treatment, either Ephrin B2 was applied (gray) or not (black) (n=1). Panel B shows survival of in 
normoxia (21 %) cultivated A549 WT and EPORKO in response to Gemcitabine treatment. Prior to treatment, 
either Stem Cell Factor was applied (gray) or not (black) (n=1). Panel C shows survival of in normoxia (21 %) 
cultivated A549 WT and EPORKO in response to Gemcitabine treatment. Prior to treatment, either 
Thrombospondin-1 was applied (gray) or not (black) (n=1). The survival rate was analyzed by clonogenic assay 
and is shown in percent (%) to untreated controls of the respective EPOR expressing or deficient cell lines. A 




Because the three potential candidates did not protect A549 lung cancer cells, we 
analyzed the proteome of exosomes isolated from normoxic and hypoxic 
preconditioned medium of A549 cells by mass-spectroscopy. We used a qualitative, 
not a quantitative approach to identify the proteins that were contained in the 
exosomal fraction. The data shows that a large number of bovine proteins was 





clean. However, mass-spectroscopy is a very sensitive approach and small amounts of 
protein contamination can be easily identified [90]. Among the human proteins that 
were identified by mass-spectroscopy in the exosomal fraction, three candidates were 
detected that are potentially receptor binding ligands: 14-3-3ζ (YWHAZ) protein, 
Clusterin (CLU) and Inducible T- cell co- stimulator ligand (ICOSLG). Although the 
number of identified peptides of a protein is only a weak indicator of protein quantity, 
we detected more peptides in the exosomal fraction of hypoxic preconditioned 
medium, suggesting that these candidates might be upregulated by hypoxia. To test 
this, we quantified mRNA expression of normoxia and hypoxia exposed A549 lung 
cancer cells. Gene expression of both, ICOSLG (Fig.9 A) and YWHAZ (Fig.9 C) is 
induced 1.9 times and 2.2 times, respectively. CLU gene expression is not induced 
during hypoxia (Fig 9 B) and it might even be downregulated. Thus, we concluded 
that YWHAZ and ICOSLG are promising candidates, to be tested in future studies, 
that might confer protection against chemo- and radiotherapy in lung cancer cells in 





















        
 
Fig. 9 Relative gene expression levels of ICOSLG, Clusterin and YWHAZ in normoxia and hypoxia exposed 
A549 cells. 
Real Time PCR was performed using cDNA of the A549 WT in normoxic (21% O2; black bars) and hypoxic (1% 
O2; gray bars) conditions. The results obtained were normalized to β-actin (calibrator) and fold changes were 
calculated using the ΔΔCt method. The samples were run in duplicates. Panel A shows the ICOSLG expression of 
A549 WT cells (n=3). Panel B shows the CLU expression of A549 WT cells (n=3). Panel C shows the YWHAZ 
expression of A549 WT cells (n=3). A Students t-test was performed for statistics. (Mean ± SD; n=3-4; *= 



























In this study we illustrated the importance of EPOR in A549 and H661 lung cancer 
cells in maintaining therapy resistance. To test if EPO-EPOR protect lung cancer cells 
from chemo- and radiotherapy, we generated A549 and H661 EPOR knockout cells 
by CRISPR/Cas. We show in in vitro experiments that EPO neither protects lung 
cancer cells from chemo- nor from radiotherapy. However, the expression of EPOR is 
essential for hypoxia-induced protection of A549 and H661 lung cancer cell from 
chemo- and radiotherapy. We illustrate that the protective effect of EPOR under 
hypoxia is also EPO independent. Further, we display that hypoxia preconditioned 
medium protects EPOR expressing but not EPORKO lung cancer cells. This suggests 
that EPOR requires an alternative ligand, which is secreted by hypoxia-exposed cells, 
to protect cancer cells in a paracrine manner. Our data suggest that the ligand is a 
protein, because heat-inactivation reduces the protective effect of hypoxia 
preconditioned medium. Further, we show that this alternative EPOR ligand might be 
packed into and released from exosomes and we provide promising candidate ligands 
for future studies by analyzing the exosome proteome. 
The large amount of bovine proteins in exosomes might result from cellular 
resorption of bovine proteins, which were packed into exosomes, although such a 
mechanism has not been described yet. 
Cancer cells have been suspected to express EPOR [2], [13], [22] [59] and thus, EPO 
might increase tumor growth or malignancy. Indeed, a recent study showed EPOR 
protein expression in human cancer cell lines as well as human patients [16]. 
Preclinical studies showed that EPO and EPOR control proliferation of breast cancer 
stem cells [92], in vivo growth of glioma [92], as well as resistance to chemotherapy 
in a glioma mouse model [92]. However, the role of EPO/EPOR in protection of lung 
cancer cells from chemo- and radiotherapy has not yet been studied  
We used two lung carcinoma cell lines, namely A549 and H661. A549 cells have 
previously been reported to express EPOR in vitro [22] and in vivo [93].We confirm 
EPOR expression of A549 cells in vitro and show that also H661 cells express EPOR 
in vitro. Afterwards, we generated EPOR knockout (EPORKO) clones by 
CRISPR/Cas to study the role of EPO/EPOR in lung cancer cell resistance against 





Our data show that EPO administration does not protect A549 and H661 lung cancer 
cell from chemo- and radiotherapy. This contradicts the findings of Debeljak.N., et al, 
2014 [112] who found a growth- promoting, anti-apoptotic action of EPO on MDA-
MB-435 cells that were treated with radiation. Furthermore, Belenkov, et al, 2004 [57] 
showed that the presence of EPO in cultured media increases the survival of U87 and 
H100 cells after the application of cisplatin and radiation. However, although EPO 
did not protect A549 and H661 lung cancer cell from chemo- and radiotherapy, we 
show that the expression of EPOR is essential for better protection: Both, A549 and 
H661 cells are protected from radiation as well as Gemcitabine and Taxol when 
cultivated under hypoxic conditions. Hypoxia is a strong stimulus that activates 
cellular survival programs and protects healthy [95] and cancer cells [94], [95] from 
cytotoxic compounds. We show that the hypoxia-induced resistance to chemo- and 
radiotherapy is lost in EPOR lacking A549 and H661 cancer cells. Also, EPOR-
lacking glioma cells have been reported to be more sensitive to Temozolomide in vivo 
[111], indicating that EPOR might play a critical role in cancer cell protection beyond 
lung cancer cells. 
Why do lung cancer cells require EPOR for protection from chemo- and radiotherapy 
but do not respond to EPO treatment? In line with this study, a previously conducted 
study on EPOR expression in A549 lung cancer cells showed no measurable response 
to EPO [22]. Also, some breast cancer cells were reported to be non-responding to 
EPO despite a functional role of EPOR in cancer cells [96]. Thus, our data and the 
aforementioned studies suggest that EPOR might not require EPO to be activated. 
This independence of EPO could be explained by five different reasons, illustrated in 
Figure 10. Firstly, the expression of EPO could be induced during hypoxia, whereas 
the endogenous EPO of the cancer itself is increased. This could be enough to saturate 
all the EPOR, resulting in no further EPOR activation by the application of rhEPO 
[97]. Secondly, EPOR might require a co- stimulating factor, which could be another 
reason for why the cancer cells did not respond to rhEPO. This theory states that 
while EPO binds to EPOR, another ligand, Factor X, needs to bind to its 
corresponding Receptor X, for therapy-resistance to occur [22]. Therefore, solely 
applying rhEPO did not allow for the desired effect to occur. Another possibility is 
that although the FCS used was heat-inactivated, the bovine EPO is still (partially) 





[57]. In this scenario, all the EPORs on cancer cells were already saturated and fully 
activated by bovine EPO before the application of rhEPO. As a fourth reason, non-
ligand induced activation could account for the non-responsiveness of EPOR to the 
administered rhEPO. As shown by Kourounioutis, et al, 2016 [82], certain receptors 
are activated without the binding of a ligand. Lastly, an alternative ligand [22] could 
bind to EPOR, making us see no effect when applying rhEPO. EPO can act as an 
alternative ligand for the Ephrin B4 receptor [15]. It is not clear whether EphrinB2 
(EFNB2), or another alternative ligand, may also be able to bind and activate the 
heterodimeric isoform of EPOR, which is the isoform where EPO has a reduced 




     
 
 
Fig.10 Possible scenarios of how EPOR induces therapy resistance in hypoxia 
Illustrated are the five possible scenarios of EPO-dependent and independent mechanisms that result in resistance. 
Scenario 1 illustrates endogenously produced EPO by cancer cells, which binds to EPOR. Scenario 2 suggests a 
co-stimulation, where EPO binds to the EPOR but simultaneously requires a co-stimulus to protect cancer cells. In 
scenario 3, bovine not human EPO (contained in FCS) binds to EPOR. Scenario 4 shows the non-ligand induced 
auto-stimulation of EPOR and scenario 5 illustrates the alternative ligand theory, where an alternative ligand 
instead of EPO binds to EPOR.  
 
 
To decipher how EPOR protects lung cancer cells from chemo-and radiotherapy 
during hypoxia, we tested if endogenously produced EPO during hypoxia activates 
EPOR. However, when we used soluble EPOR prior to radiation to sequester 





cells were still protected from chemo- and radiotherapy. Thus, neither endogenously 
produced nor FCS-born bovine EPO are required for EPOR activation in hypoxic 
lung cancer cells. To confirm these results in an independent experiment, we used the 
EPOR antagonist EMP9 [81]. The incubation of EMP9 did not prevent EPOR 
dependent protection of hypoxia-exposed cells from chemo- and radiotherapy. This 
experiment confirms that EPO is not required for EPOR dependent protection. 
Furthermore, it implies that EPOR may not exist in a homodimeric form in lung 
cancer cells. The existence of EPOR as a heterodimer has been proposed [58] and 
verified [23]. We detected the expression of the b-common receptor (CD131) in A549 
lung cancer cells (supplemental Fig. 4), suggesting that the heterodimeric EPOR 
might exist in lung cancer cells.  However, also the EPOR heterodimer with the b-
common receptor is EPO responsive [98], suggesting that there might be a third 
EPOR version in cancer cells, by which the hypoxia-induced therapy resistance 
functions. Thus, we concluded that EPOR dependent protection from chemo- and 
radiotherapy is completely independent of EPO. Neither endogenously expressed or 
administered human nor FCS-born bovine EPO as a single stimulant or as a co-
stimulant with a second factor, are involved in hypoxia-induced cell protection.  
To test the two remaining scenarios, the non-ligand induced autoactivation of EPOR 
as described by Naranda, et al, 2002 [113], and the alternative ligand scenario, we 
used hypoxia preconditioned medium to determine if a secreted factor is enough to 
protect lung cancer cells from chemo- and radio- resistance.  
In fact, hypoxia preconditioned medium was enough to protect normoxia incubated 
A549 and H661 WT but not EPORKO cells from chemo- and radiotherapy. This 
suggest that EPOR requires a ligand and might not be activated in a non-ligand 
induced fashion. When the hypoxia preconditioned medium was heat-inactivated, 
normoxic cells were not protected, which suggest that the ligand is protein-based. In 
previous experiments we showed that the ligand is bigger than 100 kDa [22]. Due to 
the size, we hypothesized that the ligand is packed into exosomes, which are produced 
by cancer cells [99] and can increase tumor malignancy and resistance against 
therapeutic interventions [100]. Indeed, we were able to show that an exosome 
fraction, isolated from preconditioned medium, protects normoxia-incubated WT but 
not EPORKO cells. However, also the medium fraction containing all molecules 





exosome-bound as well as free form. To identify the ligand, we analyzed the exosome 
isolated proteome from normoxic and hypoxic preconditioned medium. We identified 
83 proteins, which is a little less than cited in the previous literature [101]. Among the 
identified proteins, we discovered three proteins that are able to act as ligands: 1. 
YWHAZ, is a protein that classically binds to a large spectrum of partners such as; 
cadherine binding, identical protein binding, ion channel binding, RNA binding, etc. 
[103]. It is frequently upregulated in various types of cancers, acting as an oncogene 
by increasing cell growth, cell cycle, apoptosis, migration, invasion and metastasis 
[60]. Further, YWHAZ interacts with HIF-1α under hypoxic conditions and enhances 
its protein stability, inducing cell migration and invasion. Recent studies showed that 
Gemcitabine resistant cells upregulated the expression of YWHAZ [44], suggesting 
that it is a promising candidate to evaluate. 2. We identified Clusterin that suppresses 
DNA damage-induced cell death in tumor cells, and is often overexpressed in breast- 
cancer [45]. Clusterin binds to the endocytic receptor Megalin [105] and was thus, 
considered to be a potential ligand [104]. 3. The third identified protein was ICOSLG, 
which has been reported to be associated with a poor prognosis in patients with 
Glioblastoma [51]. ICOSLG induces IL-10 production in T-cells, which further 
promotes regulatory T-cell- mediated peripheral tolerance [51]. T- Lymphocytes can 
be separated into three different groups based on their function; Cytotoxic T Cells 
( CD 8+), Helper Cells ( CD 4+), and regulatory T Cells (Tregs) [106]. Tregs play an 
essential role in maintaining self-tolerance. Therefore, they are capable of suppressing 
anticancer immunity, thus promoting tumor development and progression[107]. 
Through its influence on Tregs, ICOSLG was another candidate to look into.   
We analyzed if the gene expression of the three candidate proteins was hypoxia-
inducible to estimate if the three candidates are involved in EPOR-mediated 
protection of A549 and H661 lung cancer cells from chemo- and radiotherapy. We 
observed that gene expression of both, YWHAZ and the ICOSLG was slightly 
increased during hypoxia. In contrast, Clusterin was expressed at an even lower rate 
during hypoxia. Thus, YWHAZ and ICOSLG are two promising candidates that 
might stimulate an EPOR-heterodimer and protect lung cancer cells from chemo- and 











Fig.11 A new hypothesis: Alternative ligands stimulate a heterodimeric EPO Receptor 
Illustrated are two possible ligands, YWHAZ and ICOSLG, which were found in exosomes and could stimulate 
the, potentially heterodimeric, EPOR resulting in hypoxia- induced chemo- and radio-resistance. Scenario 1 
illustrates how ICOSLG could function as a possible alternative ligand binding on a heterodimeric EPO Receptor. 
Scenario 2 displays another possible ligand, YWHAZ, binding on to a heterodimeric EPO Receptor, which leads 
to the hypoxia induced therapy resistance.   
6.1  Outlook 
 
The future goal is to identify the ligand that binds a heterodimeric form of EPOR 
resulting in therapy resistance of A549 and H661 lung cancer cells. Because YWHAZ 
and ICOSLG were identified in exosomes of hypoxia preconditioned medium, and 
both promote cancer, both factors are promising candidates for future research 
projects. Both proteins could be applied to or overexpressed in A549 and H661 WT 
cells under normoxic conditions, to test their potential to protect lung cancer cells 
from chemo- and radiotherapy. EPORKO cells can be used to test if the ligands, given 
that they mediate cancer cell protection, protect by binding or interacting with EPOR. 
An aspect that has not been addressed in our study is the classical EPOR/JAK2/STAT 
pathway: In a future study, it is important to analyze if therapy resistance is mediated 
via the classical EPOR/JAK2/STAT pathway, which can be tested by AG490, a JAK2 





6.2  Conclusion  
 
In conclusion, we showed that EPOR is required for hypoxia-induced resistance to 
chemo- and radiotherapy in A549 and H661 lung cancer cells. We further show that 
EPO is not required for the EPOR-mediated protection and suggest an alternative 
ligand that binds a (potentially) heterodimeric EPO Receptor. Although we show that 
EPOR but not EPO itself protected lung cancer cells from therapeutic approaches, we 
recommend that EPO treatment of anemic cancer patients is handled with care. 
However, our study indicates that cancer-specific targeting of the EPOR could be a 
possible strategy to increase the sensitivity of cancers cells to chemo- and 
radiotherapy, especially in hypoxic tumor regions. For that, the identification of the 
EPOR binding ligand as well as the identification of the EPOR heterodimer is 
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Figure 1  
 
 
Fig. 1 Testing the hypoxic chamber. 
Real Time PCR was performed using cDNA of the A549, and H661 WT in normoxic (21% O2; black bars) and 
hypoxic (1% O2; gray bars) conditions. The results obtained were normalized to β-actin (calibrator) and fold 
changes were calculated using the ΔΔCt method. The samples were run in duplicates. Panel A shows the Egln1 
expression of A549 WT cells (n=3). Panel B shows the Egln1 expression of H661 WT cells (n=3). A Students t-







Fig. 2 Therapy resistance factor must be a protein  
Figure 2 shows in normoxic (21%, black) or hypoxic (1%, gray) preconditioned medium cultivated A549 
EPORKO cells (n=3) in response to Gemcitabine treatment. The preconditioned medium was either boiled before 
application (BPcM), or not (PcM). The survival rate was analyzed by clonogenic assay and is shown in percent (%) 
to untreated controls of the respective EPOR expressing or deficient cell lines.  A Students t-test was performed 


















Fig. 3 Hypoxia-induced therapy resistance against Gemcitabine might be EPO independent 
A549 and H661 lung cancer wildtype cells (WT) and EPO receptor knockout cells (EPORKO) were incubated 
either in normoxia (21% O2, Nx) or hypoxia (1% O2, Hx) and treated with 3 Gy radiation. The survival rate was 
analyzed by clonogenic assay and is shown in percent (%) to untreated controls of the respective EPOR expressing 
or deficient cell lines. Panels A and B show survival of in normoxia (21 %) cultivated A549 WT and EPORKO in 
response to 3 Gy radiation. Either 0.5h (A) (n=3) or 2h (B) (n=3) prior to radiation, cells were incubated with 1-4 
u/ml EPO (gray bars) or not (black bar). Panels C and D show survival of in normoxia (21 %) cultivated H661 WT 
and EPORKO in response to 3 Gy radiation. Either 0.5h (C) (n=3) or 2h (D) (n=3) prior to radiation, cells were 
incubated with 1-4 u/ml EPO (gray bars) or not (black bar). A Students t-test was performed for statistics. (Mean ± 























Fig 4: Expression of CD131 in A549 lung cancer cells 
Real Time PCR was performed using cDNA of the A549 WT (black bar) and EPORKO (gray bar) cells to 
measure the expression of CD131 of the cells. The results obtained were normalized to β-actin (calibrator) and 
fold changes were calculated using the ΔΔ Ct method. The samples were run in duplicates. (n=3). A Students t-
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